未登录

S

Schafer Boeder

university of california

H指数:14

被引数:824

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CGM-Guided Insulin Infusion in Critically Ill Patients Promotes Safety, Improves Time Efficiency, and Enhances Provider Satisfaction

连续血糖监测指导的胰岛素输注在危重患者中提升安全性、改善时间效率并提高提供者满意度

Endocrine Practice

IF4.6

2025-06-230

OAAI

Accuracy of Factory-Calibrated Continuous Glucose Monitors in Critically Ill Patients Receiving Intravenous Insulin: A Prospective Clinical Trial of Two Leading Systems

接受静脉胰岛素治疗的危重患者中，工厂校准连续血糖监测仪的准确性：一项两种领先系统的前瞻性临床研究

JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY

IF3.7

2025-05-080

PRE

Acetazolamide Therapy and Kidney Function in Persons with Nonalbuminuric Diabetes Mellitus Type 1

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

IF9.4

2024-10-080

PRE

Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin

DIABETES TECHNOLOGY & THERAPEUTICS

IF6.3

2024-09-016

PRE

Combination SGLT2 Inhibitor and Glucagon Receptor Antagonist Therapy in Type 1 Diabetes: A Randomized Clinical Trial

IF16.6

2024-05-223

OAAI

Continuous Glucose Monitoring Time Below Range Predicts Impaired Epinephrine Response to Hypoglycemia in Patients With Type 1 Diabetes

IF16.6

2024-02-230

OAAI

The Stomach Looks Suspicious, But Is It Pernicious?

GASTROENTEROLOGY

IF25.1

2023-12-010

OA

Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia

DIABETES OBESITY & METABOLISM

IF5.7

2023-04-2014

OA

Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial (vol 28, pg 2092, 2022)

NATURE MEDICINE

IF50

2023-03-170

OA

Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial

NATURE MEDICINE

IF50

2022-10-0333

OA

Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2022-09-2985

OA

Russell, Steven J.; Beck, Roy W.; Damiano, Edward R.; El-Khatib, Firas H.; Ruedy, Katrina J.; Li, Zoey; Balliro, Courtney A.; Calhoun, Peter; Wadwa, R. Paul; Buckingham, Bruce; Zhou, Keren; Daniels, Mark; Raskin, Philip; White, Perrin C.; Lynch, Jane; Pettus, Jeremy; Hirsch, Irl B.; Goland, Robin; Buse, John B.; Kruger, Davida; Mauras, Nelly; Muir, Andrew; McGill, Janet B.; Cogen, Fran; Weissberg-Benchell, Jill; Sherwood, Jordan S.; Castellanos, Luz E.; Hillard, Mallory A.; Tuffaha, Marwa; Putman, Melissa S.; Sands, Mollie Y.; Forlenza, Gregory; Slover, Robert; Messer, Laurel H.; Cobry, Erin; Shah, Viral N.; Polsky, Sarit; Lal, Rayhan; Ekhlaspour, Laya; Hughes, Michael S.; Basina, Marina; Hatipoglu, Betul; Olansky, Leann; Bhangoo, Amrit; Forghani, Nikta; Kashmiri, Himala; Sutton, Francoise; Choudhary, Abha; Penn, Jimmy; Jafri, Rabab; Rayas, Maria; Escaname, Elia; Kerr, Catherine; Favela-Preza, Ruby; Boeder, Schafer; Trikudanathan, Subbulaxmi; Williams, Kristen M.; Leibel, Natasha; Kirkman, M. Sue; Bergamo, Kate; Klein, Klara R.; Dostou, Jean M.; Machineni, Sriram; Young, Laura A.; Diner, Jamie C.; Bhan, Arti; Jones, J. Kimberly; Benson, Matthew; Bird, Keisha; Englert, Kimberly; Cedeno, Andrea; Permuy, Joe; Cossen, Kristina; Felner, Eric; Salam, Maamoun; Silverstein, Julie M.; Adamson, Samantha; Meighan, Seema; Dauber, Andrew

Accuracy and Glycemic Efficacy of Continuous Glucose Monitors in Critically Ill COVID-19 Patients: A Retrospective Study

JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY

IF3.7

2022-07-2515

OAAI

Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes

DIABETES OBESITY & METABOLISM

IF5.7

2022-06-044

OA

COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes (vol 44, pg 526, 2021)

IF16.6

2022-03-021

OA

SGLT2 Inhibition Increases Fasting Glucagon but Does Not Restore the Counterregulatory Hormone Response to Hypoglycemia in Participants With Type 1 Diabetes

IF7.5

2021-12-028

OA

SGLT2 Inhibition Has No Effect on the Counterregulatory Response to Hypoglycemia in Subjects with Type 1 Diabetes (T1D)

IF7.5

2021-06-010

PRE

Volagidemab, a Human Glucagon Receptor Antagonist, Improves Glycemic Control in Subjects with Type 1 Diabetes (T1D): A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

IF7.5

2021-06-011

PRE

COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes

IF16.6

2020-12-02192

OA

Effects of Glucagon Receptor Antagonism (GRA) on Ketone Body Formation during Insulinopenia in Type 1 Diabetes (T1D)

IF7.5

2020-06-010

PRE

RESPONSE TO COMMENT ON GREGORY ET AL. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes. Diabetes Care 2021;44:526-532

IF16.6

2020-05-100

OAAI